NeuroBell

NeuroBell is a medtech start-up based in Cork, Ireland, founded in 2023 by Dr. Mark O’Sullivan, Dr. Alison O’Shea, and Colm Murphy. The company focuses on developing innovative medical devices for portable EEG monitoring with automated neonatal seizure detection at the bedside of neonatal intensive care units (NICUs). The core product is an AI-powered medical device that accurately detects seizures in newborns in real time. This technology addresses a critical need, as seizures are a common sign of brain injury in newborns and often require specialized monitoring. By integrating deep learning AI with clinically annotated EEG data, NeuroBell's device facilitates early intervention, improving patient outcomes and reducing the risk of long-term neurological issues. The company is currently finalizing design for manufacture and cloud integration, with plans to seek FDA approval in early 2025 after successful clinical testing. NeuroBell has secured €2.1 million in seed funding to support product development and clinical trials, with plans to expand its team. The leadership team is complemented by experts in neonatology and neurosurgery, ensuring a strong foundation for advancing neonatal care.

• Employees 13
• Founded 2022